BIOCORP announces the CE marking of SoloSmart®, an accessory medical device for SANOFI Solostar® pens at the occasion of EASD
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and SANOFI announced the completion of the development of SoloSmart® today, on the opening of the EASD (European Association for the Study of Diabetes) annual meeting in Stockholm, Sweden. SoloSmart® is fully compatible with the pharmaceutical group's SoloStar® injection pens.
The result of the collaboration initiated in 2019 between the two companies is presented as an accessory to the Sanofi SoloStar®/ DoubleStar® insulin pens, which records information about the insulin dose, time and date of each injection and transmits it via Bluetooth to a compatible mobile application. The SoloSmart® device automatically and accurately records injected doses, eliminating the need for manual logbooks and possibly allows for adapting to new patient uses of continuous glucose monitoring systems or connected BGM.
Developed by BIOCORP's R&D department, SoloSmart® meets the latest requirements of the new European medical device regulation. Its commercial launch will begin early 2023 in the distribution networks approved by SANOFI and its partners. This partnership strategic step validates a substantial milestone - more details will be given on September 29th (half year results).
Eric Dessertenne, CEO of BIOCORP, said: "The expertise we have developed with Mallya leads us to improve and develop a new device by miniaturizing it, keeping data reliability. We are today very proud of developments achieved by our respective R&D and to present them today at the EASD, which brings together an international diabetes community. The strength of this industrial and commercial partnership has resulted in a technological achievement which will allow people living with diabetes, users of SoloStar ® pens, to benefit from a solution that improves their daily life thanks to a presentation that is very compact but still secure and accurate.”
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220918005029/en/
Contact information
CONTACTS BIOCORP
Jacques Gardette
Chairman of the Board
Éric Dessertenne
Chief Executive Officer
Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
CONTACTS ULYSSE COMMUNICATION
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 47 26
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LevelBlue to Acquire Trustwave, Becoming Largest Pure-Play Managed Security Services Provider1.7.2025 15:00:00 EEST | Press release
LevelBlue, a global leader in cloud-based, AI-driven managed security services (MSS), has signed a definitive agreement to acquire Trustwave, a global provider of cybersecurity and managed detection and response (MDR) services from the MC2 Security Fund (MC2), a private equity fund sponsored by The Chertoff Group, an internationally recognized security and growth advisory firm. This strategic acquisition complements LevelBlue’s recent agreement to acquire Aon’s cybersecurity consulting business, formerly known as Stroz Friedberg, and further strengthens the company’s market leadership, uniting two leading Managed Security Service Providers (MSSPs) to deliver unparalleled cybersecurity outcomes through a comprehensive and expanded suite of services designed to stay ahead of the rapidly evolving threat landscape. The acquisition will create the largest pure-play MSSP in the industry. The acquisition will integrate LevelBlue’s extensive expertise in strategic risk management and cybersecu
Vertex Announces European Commission Approval of ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis1.7.2025 14:34:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across the EU may now benefit from this new, once-daily medicine, which has demonstrated further improvement in CFTR protein function versus KAFTRIO,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “With this approval, we are one step closer to our ultimate goal of restoring normal levels of CFTR function in people living with CF.” In two head-to-head pivotal clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor on ppFEV1 and superior at reducing sweat chloride, demonstrating greater improvem
LTIMindtree Launches GCC-as-a-Service1.7.2025 12:30:00 EEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company today introduced its GCC-as-a-Service. The services cater to organizations that may want to set up GCCs, scale their existing ones to optimize costs and create added value. The catalogue covers a spectrum of Build, Operate, Transform and Transfer services, offering clients the option to pick and choose what they require. GCC-as-a-Service commercials are designed on a per-seat or per service basis to ensure cost optimization and value realization. LTIMindtree’s Talent Solutions, part of our Build Services enables clients efficiently onboard business-ready talent from day one through its in-house AI-powered talent acquisition ecosystem. As a part of Transform Services, the Company provides industry specific offerings; technological solutions and frameworks that lead to acceleration of value realization. Clients will be able to leverage its BlueVerse Agentic AI Ecosystem with industry and fu
Network Failures Cost $5M A Year for More Than a Quarter of Global Businesses, According to Expereo1.7.2025 11:00:00 EEST | Press release
Network instability is taking a serious toll on global businesses, with over a quarter (28%) reporting revenue losses of up to $5 million due to network outages or poor performance. Alarmingly, an additional 23% have experienced losses exceeding $5 million. These findings come from an IDC InfoBrief commissioned by Expereo, titled “Enterprise Horizons 2025: Technology Leaders Priorities: Achieving Digital Agility.” Following a series of high-profile IT disruptions over the past year, ranging from cybersecurity breaches to connectivity failures, nearly half (49%) of global businesses have been compelled to re-evaluate their technology infrastructure, and 40% of global tech leaders say it’s caused networking and connectivity to rise higher up the C-suite agenda. Perhaps as a result, networking/connectivity now comes out on top in terms of the technologies global businesses will prioritise in terms of financial investment over the next 12 months (43%). This is followed by Cybersecurity (38
Record Financing for NeXtWind: €1.4 Billion for the Expansion of Wind Energy in Germany1.7.2025 10:52:00 EEST | Press release
NeXtWind, a leading renewable energy company, has secured €1.4 billion in debt financing. The agreement also includes an additional €1.3 billion in so-called accordion facilities, which can be activated in tranches over the coming years. This syndicated loan is the largest of its kind for an independent wind energy provider in Germany, and it opens the onshore wind market to debt investments from major financial institutions both domestically and internationally. NeXtWind will use the new financing to modernize more than half of its wind farms, increasing their generation capacity to over 1 GW by 2028. Subsequently, the company plans to further develop these wind farms into sustainable energy infrastructure hubs. “This financing is a significant milestone for NeXtWind and testament to the confidence in our business model,” explains Lars B. Meyer, Co-CEO of NeXtWind. “Thanks to this novel platform approach, we can optimize our wind farms more quickly and accelerate our growth. In the lo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom